Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultrasound Screening Criteria Proposed for Diagnosing Polycystic Kidney Disease

By MedImaging International staff writers
Posted on 11 Nov 2008
Modification of the current screening criteria for diagnosing patients with autosomal dominant polycystic disease (ADPKD) is needed, according to researchers. Their study's findings suggest that some patients with a milder form of the disease may otherwise be misdiagnosed.

ADPKD, a genetic disorder characterized by the growth of numerous cysts in the kidneys, can lead to reduced kidney function and kidney failure. It is the most common inherited disorder of the kidney, occurring in approximately 1 in 500 births, and symptoms typically develop between the ages of 30 and 40 years.

Individuals at risk for developing ADPKD are commonly screened by imaging techniques such as ultrasound. Diagnosis can also be made with a genetic test that detects mutations in the two genes that cause the disease, called PKD1 and PKD2. However, gene-based diagnosis is expensive and detects definitive mutations in only 41% to 63% of cases. In many clinical settings, it is rarely performed.

Testing for ADPKD in individuals whose families have a history of the disease is important. Young people who know they are affected may be able to better preserve their kidney function through diet, life style modification, and blood pressure control. Testing also can be used to determine whether an at-risk individual can safely donate a kidney to a family member with the disease.

Ultrasound screening for ADPKD is based on diagnostic criteria developed to detect cases caused by mutations in the PKD1 gene. This form of the disease is more common and more severe than the form caused by mutations in the PKD2 gene. Therefore, there may be a need for different diagnostic criteria for patients with the milder, less common form of autosomal dominant polycystic disease.

To test whether this is the case, York Pei, M.D., of the University of Toronto (Toronto, ON, Canada) and his colleagues performed kidney ultrasounds and genetic tests on 577 and 371 at-risk individuals from 58 PKD1 and 39 PKD2 families, respectively. The researchers found that the ultrasound diagnostic criteria currently in use may misdiagnose individuals with mutations in the PKD2 gene. Therefore, the investigators devised new ultrasound criteria that could effectively detect the disease in individuals with mutations in either PKD1 or PKD2 gene.

The investigators determined that in families of unknown gene type, the presence of three or more kidney cysts is sufficient for establishing the diagnosis in individuals aged 15 to 39 years, two or more cysts in each kidney is sufficient for individuals aged 40 to 59 years, and four or more cysts in each kidney is required for individuals aged 60 years. Moreover, fewer than two kidney cysts in at-risk individuals aged 40 years is enough to exclude the disease. For at-risk individuals aged 30 to 39 years, the absence of any kidney cysts provides almost certainty that the disease is not present.

"For the first time we have derived a set of highly predictive criteria for ultrasound diagnosis of ADPKD that is suitable for test subjects with either gene type,” said Dr. Pei. "These unified diagnostic criteria will be useful for genetic counseling and for evaluation of at-risk subjects as living-related kidney donors for their affected relatives.”

The study was published online on October 22, 2008, in the Journal of the American Society of Nephrology (JASN).

Related Links:
University of Toronto


Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
X-Ray Illuminator
X-Ray Viewbox Illuminators
Pocket Fetal Doppler
CONTEC10C/CL
X-ray Diagnostic System
FDX Visionary-A

Channels

General/Advanced Imaging

view channel
Image: Example snapshots of the photon energy density at t = 0.5, 0.7, 0.9, 1.1 nanoseconds (ns) on the y = 2.0 cm plane (Horie, S., Yajima, H., Abe, M. et al., Biomedical Engineering Letters (2026). DOI: 10.1007/s13534-026-00578-9)

AI Tool Enables Real-Time Diffuse Optical Tomography for Brain Lesion Detection

Diffuse optical tomography is a noninvasive imaging technique that uses near-infrared light to detect internal abnormalities such as cerebral hemorrhage and tumors. Its clinical utility for real-time ... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.